83 FR 24319 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 102 (May 25, 2018)

Page Range		24319-24319
FR Document		2018-11220

Federal Register, Volume 83 Issue 102 (Friday, May 25, 2018)

[Federal Register Volume 83, Number 102 (Friday, May 25, 2018)]
[Notices]
[Page 24319]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-11220]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Summer Research Education Experience Programs (R25).
    Date: June 21, 2018.
    Time: 12:00 p.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
hiromi.ono@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIH Pathway to Independence Award (K99/R00).
    Date: June 25, 2018.
    Time: 12:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive 
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, 
mcguireso@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: May 21, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-11220 Filed 5-24-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices 24319

The field of use may be limited to exclusive license may be granted unless Institute on Drug Abuse, National Institutes
monovalent live attenuated Zika within thirty (30) days from the date of of Health, DHHS, 6001 Executive Boulevard,
vaccines and multivalent live attenuated this published notice, the National Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
flavivirus vaccines. The Licensed Institute of Allergy and Infectious
Territory may be limited to the United Diseases receives written evidence and Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
States of America, Canada, Mexico, argument that establishes that the grant Pathway to Independence Award (K99/R00).
Brazil and Argentina. of the license would not be consistent Date: June 25, 2018.
Zika virus (ZIKV) is an emerging with the requirements of 35 U.S.C. 209 Time: 12:00 p.m. to 5:00 p.m.
infectious disease that was first and 37 CFR part 404. Agenda: To review and evaluate grant
identified in 1947, and that has more Complete applications for a license in applications.
recently become a major public health the prospective field of use that are filed Place: National Institutes of Health,
threat around the world. ZIKV has in response to this notice will be treated Neuroscience Center, 6001 Executive
recently been shown to cause as objections to the grant of the Boulevard, Rockville, MD 20852 (Telephone
devastating neurological damage in contemplated Exclusive Conference Call).
infants and serious complications in Contact Person: Susan O. McGuire, Ph.D.,
Commercialization Patent License Scientific Review Officer, Office of
adults in some cases, and may have Agreement. Comments and objections Extramural Policy and Review, National
other effects that have not yet been submitted to this notice will not be Institute on Drug Abuse, National Institutes
identified or definitively linked to the made available for public inspection of Health, DHHS, 6001 Executive Blvd.,
virus. There are no treatments or and, to the extent permitted by law, will Room 4245, Rockville, MD 20852, (301) 827–
vaccines for this insidious virus. While not be released under the Freedom of 5817, mcguireso@mail.nih.gov.
important, current measures for Information Act, 5 U.S.C. 552. (Catalogue of Federal Domestic Assistance
mosquito control are insufficient in Program Nos.: 93.279, Drug Abuse and
Dated: May 14, 2018.
most settings to prevent the spread of Addiction Research Programs, National
the virus. Recommendations that Suzanne M. Frisbie, Institutes of Health, HHS)
women who live in or travel to endemic Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute Dated: May 21, 2018.
areas avoid pregnancy for long periods Natasha M. Copeland,
of Allergy and Infectious Diseases.
of time are unrealistic, particularly in
[FR Doc. 2018–11257 Filed 5–24–18; 8:45 am] Program Analyst, Office of Federal Advisory
contexts where access to reproductive Committee Policy.
services is limited, and threaten to leave BILLING CODE 4140–01–P
[FR Doc. 2018–11220 Filed 5–24–18; 8:45 am]
those most likely to suffer the
BILLING CODE 4140–01–P
devastating consequences of Zika
without effective protection. There is DEPARTMENT OF HEALTH AND
therefore urgent need to develop HUMAN SERVICES
DEPARTMENT OF HEALTH AND
biomedical interventions in parallel National Institutes of Health HUMAN SERVICES
with ongoing public health efforts
against ZIKV. National Institute on Drug Abuse; National Institutes of Health
No vaccine exists today to prevent Notice of Closed Meetings
ZIKV infections. The methods and National Institute on Drug Abuse;
compositions of this invention provide Pursuant to section 10(d) of the Notice of Closed Meetings
a means for prevention of ZIKV Federal Advisory Committee Act, as
infection by immunization with live amended, notice is hereby given of the Pursuant to section 10(d) of the
attenuated, immunogenic viral vaccines following meetings. Federal Advisory Committee Act, as
against ZIKV and/or Dengue virus. The meetings will be closed to the amended, notice is hereby given of the
Many entities, governmental, public in accordance with the following meetings.
academic, and commercial, are actively provisions set forth in sections The meetings will be closed to the
pursuing development of ZIKV vaccines 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., public in accordance with the
each using a different approach to as amended. The grant applications and provisions set forth in sections
address this public health need. The the discussions could disclose 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
U.S. Government is coordinating its confidential trade secrets or commercial as amended. The contract proposals and
vaccine development response to ZIKV property such as patentable material, the discussions could disclose
and has published this plan at https:// and personal information concerning confidential trade secrets or commercial
www.phe.gov/Preparedness/planning/ individuals associated with the grant property such as patentable material,
Pages/zika-white-paper.aspx. applications, the disclosure of which and personal information concerning
Vaccine development approaches for would constitute a clearly unwarranted individuals associated with the contract
ZIKV include but are not limited to invasion of personal privacy. proposals, the disclosure of which
inactivated virus (dead virus), live would constitute a clearly unwarranted
Name of Committee: National Institute on
attenuated virus (weakened virus), Drug Abuse Special Emphasis Panel;
invasion of personal privacy.
recombinant viral vectors (weakened Summer Research Education Experience Name of Committee: National Institute on
virus with target genes added), and Programs (R25). Drug Abuse Special Emphasis Panel; SBIR
subunit (portion of a virus) as well as Date: June 21, 2018. Phase II ‘‘Analytical Tools for Scholarly
mRNA- and DNA-based (gene-targeted). Time: 12:00 p.m. to 1:30 p.m. Research Assessment and Decision in the
These various strategies provide Agenda: To review and evaluate grant Biomedical Enterprise’’ (1214, 1217).
amozie on DSK3GDR082PROD with NOTICES1

multiple redundancies, expanded applications. Date: May 31, 2018.
Place: National Institutes of Health, Time: 11:00 a.m. to 1:00 p.m.
choice, and ensure short and long term Neuroscience Center, 6001 Executive Agenda: To review and evaluate contract
maximal benefits to the public. Boulevard, Rockville, MD 20852 (Telephone proposals.
This notice is made in accordance Conference Call). Place: National Institutes of Health,
with 35 U.S.C. 209 and 37 CFR part 404. Contact Person: Hiromi Ono, Ph.D., Neuroscience Center, 6001 Executive
The prospective exclusive license will Scientific Review Officer, Office of Boulevard, Rockville, MD 20852 (Telephone
be royalty bearing, and the prospective Extramural Policy and Review, National Conference Call).

VerDate Sep<11>2014 18:28 May 24, 2018 Jkt 241001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\25MYN1.SGM 25MYN1

Document Created: 2018-05-25 02:12:37
Document Modified: 2018-05-25 02:12:37

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		June 21, 2018.
FR Citation		83 FR 24319

83 FR 24319 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 102 (May 25, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health